Diffusion of dihydropyridine calcium channel antagonists in cardiac sarcolemmal lipid multibilayers - PubMed (original) (raw)
Diffusion of dihydropyridine calcium channel antagonists in cardiac sarcolemmal lipid multibilayers
D W Chester et al. Biophys J. 1987 Dec.
Abstract
A membrane bilayer pathway model has been proposed for the interaction of dihydropyridine (DHP) calcium channel antagonists with receptors in cardiac sarcolemma (Rhodes, D.G., J.G. Sarmiento, and L.G. Herbette. 1985. Mol. Pharmacol. 27:612-623) involving drug partition into the bilayer with subsequent receptor binding mediated (though probably not rate-limited) by diffusion within the bilayer. Recently, we have characterized the partition step, demonstrating that DHPs reside, on a time-average basis, near the bilayer hydrocarbon core/water interface. Drug distribution about this interface may define a plane of local concentration for lateral diffusion within the membrane. The studies presented herein examine the diffusional dynamics of an active rhodamine-labeled DHP and a fluorescent phospholipid analogue (DiIC16) in pure cardiac sarcolemmal lipid multibilayer preparations as a function of bilayer hydration. At maximal bilayer hydration, the drug diffuses over macroscopic distances within the bilayer at a rate identical to that of DiI (D = 3.8 X 10(-8) cm2/s), demonstrating the overall feasibility of the membrane diffusion model. The diffusion coefficients for both drug and lipid decreased substantially as the bilayers were dehydrated. While identical at maximal hydration, drug diffusion was significantly slower than that of DiIC16 in partially dehydrated bilayers, probably reflecting differences in mass distribution of these probes in the bilayer.
Similar articles
- Diffusional dynamics of an active rhodamine-labeled 1,4-dihydropyridine in sarcolemmal lipid multibilayers.
Mason RP, Chester DW. Mason RP, et al. Biophys J. 1989 Dec;56(6):1193-201. doi: 10.1016/S0006-3495(89)82766-3. Biophys J. 1989. PMID: 2611332 Free PMC article. - Molecular basis for the inhibition of 1,4-dihydropyridine calcium channel drugs binding to their receptors by a nonspecific site interaction mechanism.
Young HS, Skita V, Mason RP, Herbette LG. Young HS, et al. Biophys J. 1992 May;61(5):1244-55. doi: 10.1016/S0006-3495(92)81933-1. Biophys J. 1992. PMID: 1318093 Free PMC article. - Interaction of 1,4 dihydropyridine calcium channel antagonists with biological membranes: lipid bilayer partitioning could occur before drug binding to receptors.
Herbette LG, Vant Erve YM, Rhodes DG. Herbette LG, et al. J Mol Cell Cardiol. 1989 Feb;21(2):187-201. doi: 10.1016/0022-2828(89)90861-4. J Mol Cell Cardiol. 1989. PMID: 2545886 - Lipid lateral diffusion and membrane heterogeneity.
Lindblom G, Orädd G. Lindblom G, et al. Biochim Biophys Acta. 2009 Jan;1788(1):234-44. doi: 10.1016/j.bbamem.2008.08.016. Epub 2008 Sep 6. Biochim Biophys Acta. 2009. PMID: 18805393 Review.
Cited by
- Usefulness of targeting lymphocyte Kv1.3-channels in the treatment of respiratory diseases.
Kazama I, Tamada T, Tachi M. Kazama I, et al. Inflamm Res. 2015 Oct;64(10):753-65. doi: 10.1007/s00011-015-0855-4. Epub 2015 Jul 24. Inflamm Res. 2015. PMID: 26206235 - Physiological significance of delayed rectifier K(+) channels (Kv1.3) expressed in T lymphocytes and their pathological significance in chronic kidney disease.
Kazama I. Kazama I. J Physiol Sci. 2015 Jan;65(1):25-35. doi: 10.1007/s12576-014-0331-x. Epub 2014 Aug 6. J Physiol Sci. 2015. PMID: 25096892 Free PMC article. Review. - Ligands, their receptors and ... plasma membranes.
Vauquelin G, Packeu A. Vauquelin G, et al. Mol Cell Endocrinol. 2009 Nov 13;311(1-2):1-10. doi: 10.1016/j.mce.2009.07.022. Epub 2009 Jul 30. Mol Cell Endocrinol. 2009. PMID: 19647036 Free PMC article. Review. - Molecular mechanisms for the persistent bronchodilatory effect of the beta 2-adrenoceptor agonist salmeterol.
Szczuka A, Wennerberg M, Packeu A, Vauquelin G. Szczuka A, et al. Br J Pharmacol. 2009 Sep;158(1):183-94. doi: 10.1111/j.1476-5381.2009.00296.x. Epub 2009 Jul 7. Br J Pharmacol. 2009. PMID: 19594756 Free PMC article. - Synergistic effect of amlodipine and atorvastatin in reversing LDL-induced endothelial dysfunction.
Mason RP, Kubant R, Heeba G, Jacob RF, Day CA, Medlin YS, Funovics P, Malinski T. Mason RP, et al. Pharm Res. 2008 Aug;25(8):1798-806. doi: 10.1007/s11095-007-9491-1. Epub 2007 Dec 18. Pharm Res. 2008. PMID: 18087679
References
- Biochemistry. 1985 Jan 29;24(3):781-6 - PubMed
- J Mol Biol. 1965 Aug;13(1):238-52 - PubMed
- Mol Pharmacol. 1985 Jun;27(6):612-23 - PubMed
- Nature. 1983 Apr 28;302(5911):790-4 - PubMed
- J Biol Chem. 1957 May;226(1):497-509 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources